Venture capital firms are largely staying away from biotech, says Forbes' Bruce Booth. Reduced capital is a cyclical issue, and even with the problems in the biotech sector, bioentrepreneurs are still raising billions of dollars, he says. But what's really concerning is that the number of venture firms investing in biotech is shrinking and they're becoming less diverse.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.